preoperative docetaxel chemotherapy and radical prostatectomy for metastatic prostate cancer
- Conditions
- Prostate CancerMetastatic, untreated, high-risk
- Registration Number
- JPRN-jRCT1031180387
- Lead Sponsor
- Horie Shigeo
- Brief Summary
In both cases, the prostate cancer disease was well controlled, and the tumor marker PSA was less than 0.2 ng/mL as shown below. No.1: December 2022 PSA 0.122 ng/mL (slow PSA increase, but PSA <0.2) No.2: January 2023 PSA 0.008 ng/mL (good control) Regarding adverse events, the patients presented only minor reversible events with usual surgical care and docetaxel chemotherapy, and no events unique to this clinical trial occurred.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 2
metastatic prostate cancer
Castration-Resistant Prostate Cancer, treated prostate cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.